These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 11929752)

  • 1. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.
    Mount JD; Herzog RW; Tillson DM; Goodman SA; Robinson N; McCleland ML; Bellinger D; Nichols TC; Arruda VR; Lothrop CD; High KA
    Blood; 2002 Apr; 99(8):2670-6. PubMed ID: 11929752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver.
    Wang L; Nichols TC; Read MS; Bellinger DA; Verma IM
    Mol Ther; 2000 Feb; 1(2):154-8. PubMed ID: 10933925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy.
    Niemeyer GP; Herzog RW; Mount J; Arruda VR; Tillson DM; Hathcock J; van Ginkel FW; High KA; Lothrop CD
    Blood; 2009 Jan; 113(4):797-806. PubMed ID: 18957684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation.
    Herzog RW; Mount JD; Arruda VR; High KA; Lothrop CD
    Mol Ther; 2001 Sep; 4(3):192-200. PubMed ID: 11545609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy.
    Wang L; Calcedo R; Nichols TC; Bellinger DA; Dillow A; Verma IM; Wilson JM
    Blood; 2005 Apr; 105(8):3079-86. PubMed ID: 15637142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice.
    Crudele JM; Finn JD; Siner JI; Martin NB; Niemeyer GP; Zhou S; Mingozzi F; Lothrop CD; Arruda VR
    Blood; 2015 Mar; 125(10):1553-61. PubMed ID: 25568350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained phenotypic correction of canine hemophilia B after systemic administration of helper-dependent adenoviral vector.
    Brunetti-Pierri N; Nichols TC; McCorquodale S; Merricks E; Palmer DJ; Beaudet AL; Ng P
    Hum Gene Ther; 2005 Jul; 16(7):811-20. PubMed ID: 16000063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent expression of canine factor IX in hemophilia B canines.
    Chao H; Samulski R; Bellinger D; Monahan P; Nichols T; Walsh C
    Gene Ther; 1999 Oct; 6(10):1695-704. PubMed ID: 10516718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors.
    Chao H; Monahan PE; Liu Y; Samulski RJ; Walsh CE
    Mol Ther; 2001 Sep; 4(3):217-22. PubMed ID: 11545612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia.
    Ehrhardt A; Xu H; Dillow AM; Bellinger DA; Nichols TC; Kay MA
    Blood; 2003 Oct; 102(7):2403-11. PubMed ID: 12805062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New and improved AAVenues: current status of hemophilia B gene therapy.
    Brimble MA; Reiss UM; Nathwani AC; Davidoff AM
    Expert Opin Biol Ther; 2016; 16(1):79-92. PubMed ID: 26524468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia.
    Monahan PE; Samulski RJ; Tazelaar J; Xiao X; Nichols TC; Bellinger DA; Read MS; Walsh CE
    Gene Ther; 1998 Jan; 5(1):40-9. PubMed ID: 9536263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
    Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA
    Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy.
    Herzog RW; Fields PA; Arruda VR; Brubaker JO; Armstrong E; McClintock D; Bellinger DA; Couto LB; Nichols TC; High KA
    Hum Gene Ther; 2002 Jul; 13(11):1281-91. PubMed ID: 12162811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy.
    Finn JD; Nichols TC; Svoronos N; Merricks EP; Bellenger DA; Zhou S; Simioni P; High KA; Arruda VR
    Blood; 2012 Nov; 120(23):4521-3. PubMed ID: 22919027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector.
    Herzog RW; Yang EY; Couto LB; Hagstrom JN; Elwell D; Fields PA; Burton M; Bellinger DA; Read MS; Brinkhous KM; Podsakoff GM; Nichols TC; Kurtzman GJ; High KA
    Nat Med; 1999 Jan; 5(1):56-63. PubMed ID: 9883840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene therapy for hemophilia B: host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression.
    Fang B; Eisensmith RC; Wang H; Kay MA; Cross RE; Landen CN; Gordon G; Bellinger DA; Read MS; Hu PC
    Hum Gene Ther; 1995 Aug; 6(8):1039-44. PubMed ID: 7578416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs.
    Kay MA; Rothenberg S; Landen CN; Bellinger DA; Leland F; Toman C; Finegold M; Thompson AR; Read MS; Brinkhous KM
    Science; 1993 Oct; 262(5130):117-9. PubMed ID: 8211118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B.
    Arruda VR; Stedman HH; Haurigot V; Buchlis G; Baila S; Favaro P; Chen Y; Franck HG; Zhou S; Wright JF; Couto LB; Jiang H; Pierce GF; Bellinger DA; Mingozzi F; Nichols TC; High KA
    Blood; 2010 Jun; 115(23):4678-88. PubMed ID: 20335222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.